Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

NCT07157514 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukemia
Myeloid Leukemia
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia, in Relapse
Myelogenous Leukemia
Myelogenous Leukemia, Acute
Myelogenous Leukemia in Relapse
Transplant-Related Disorder
Allogeneic Disease
Refractory AML

Interventions

DRUG: 131I-apamistamab
DRUG: Fludarabine
DRUG: Cyclophosphamide
RADIATION: Total Body Irradiation (TBI)
BIOLOGICAL: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Sponsor

Actinium Pharmaceuticals